BR9713197A - Meios para tratamento de hipertrofia de próstata e câncer de próstata - Google Patents

Meios para tratamento de hipertrofia de próstata e câncer de próstata

Info

Publication number
BR9713197A
BR9713197A BR9713197-0A BR9713197A BR9713197A BR 9713197 A BR9713197 A BR 9713197A BR 9713197 A BR9713197 A BR 9713197A BR 9713197 A BR9713197 A BR 9713197A
Authority
BR
Brazil
Prior art keywords
prostate
alpha
cetrorelix
prostate cancer
hypertrophy
Prior art date
Application number
BR9713197-0A
Other languages
English (en)
Inventor
Juergen Engel
Thomas Reissmann
Hilde Riethmueller-Winzen
Juergen Rawert
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of BR9713197A publication Critical patent/BR9713197A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Patente de Invenção: <B>"MEIOS PARA TRATAMENTO DE HIPERTROFIA DE PRóSTATA E CâNCER DE PRóSTATA"<D>. Um regime para o manejo terapêutico de hiperplasia prostática benigna e câncer prostático emprega Cetrorelix sozinho ou em combinação com inibidores de alfa-redutase ou agentes de bloqueio de alfa-receptor. O regime reduz o volume da próstata e evita os efeitos colaterais associados com níveis de testosterona estando na faixa de castração. O Cetrorelix é administrado em dosagens entre 0,5 mg/dia a 20 mg/semana ou aproximadamente 0,014 mg/kg de peso corporal por dia a 0,30 de peso corporal por semana ou em níveis de aproximadamente 25 a 120 mg de Cetrorelix por mês ou 0,376 mg/kg a 1,71 mg/kg por mês. O Cetrorelix pode ser administrado com inibidores de alfa-redutase ou agentes de bloqueio de alfa-receptor.
BR9713197-0A 1996-09-12 1997-09-01 Meios para tratamento de hipertrofia de próstata e câncer de próstata BR9713197A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2599096P 1996-09-12 1996-09-12
US4322897P 1997-04-10 1997-04-10
PCT/EP1997/004740 WO1998010781A1 (en) 1996-09-12 1997-09-01 Means for treating prostate hypertrophy and prostate cancer

Publications (1)

Publication Number Publication Date
BR9713197A true BR9713197A (pt) 2000-04-04

Family

ID=26700570

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713197-0A BR9713197A (pt) 1996-09-12 1997-09-01 Meios para tratamento de hipertrofia de próstata e câncer de próstata

Country Status (29)

Country Link
US (4) US6054432A (pt)
EP (1) EP0925069B1 (pt)
JP (1) JP2001500500A (pt)
KR (1) KR100546235B1 (pt)
CN (1) CN1126566C (pt)
AR (1) AR009757A1 (pt)
AT (1) ATE370743T1 (pt)
AU (1) AU738306B2 (pt)
BR (1) BR9713197A (pt)
CA (1) CA2215015A1 (pt)
CZ (1) CZ298738B6 (pt)
DE (1) DE69738045T2 (pt)
DK (1) DK0925069T3 (pt)
EE (1) EE04000B1 (pt)
ES (1) ES2289764T3 (pt)
HK (1) HK1021937A1 (pt)
HU (1) HUP0000261A3 (pt)
IL (3) IL128331A0 (pt)
IS (1) IS4978A (pt)
MX (1) MXPA99002420A (pt)
NO (1) NO326207B1 (pt)
NZ (1) NZ334540A (pt)
PL (1) PL193184B1 (pt)
PT (1) PT925069E (pt)
RU (1) RU2215537C2 (pt)
SK (1) SK286174B6 (pt)
TR (1) TR199900556T2 (pt)
TW (1) TWI224002B (pt)
WO (1) WO1998010781A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
FR2768055A1 (fr) * 1997-09-11 1999-03-12 Synthelabo Utilisation de derives de sulfonanilide pour obtenir un medicament destine au traitement de l'ejaculation retrograde ou de l'aspermie
TW536402B (en) * 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
US7361680B2 (en) * 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7129262B2 (en) * 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7151100B1 (en) 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
EP1203582A4 (en) * 1999-08-09 2005-08-03 Yamanouchi Pharma Co Ltd MEDICINAL COMPOSITIONS FOR THE TREATMENT OF LOWER UROPATHY
DK1955700T3 (da) 1999-09-30 2011-05-23 Harbor Biosciences Inc Terapeutisk behandling af androgenreceptor-betingede lidelser
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
KR100876538B1 (ko) * 2000-08-17 2008-12-31 아에테르나 젠타리스 게엠베하 Ｌｈｒｈ 길항제의 염의 제조방법
DE10040700A1 (de) * 2000-08-17 2002-02-28 Asta Medica Ag Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
JP2001288115A (ja) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
WO2004026116A2 (en) * 2002-09-19 2004-04-01 The Regents Of The University Of California Use of etodoclac to treat hyperplasia
GB0301016D0 (en) * 2003-01-16 2003-02-19 Univ London Treatment of benign prostatic hyperplasia
CA2513575A1 (en) 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Treatment of benign prostatic hyperplasia using energolytic agents
TWI423943B (zh) * 2006-05-03 2014-01-21 Wisconsin Alumni Res Found Ｎ,ｎ'-雙（２，３-丁二烯基）-１，４-丁二胺之用途及包含ｎ,ｎ'-雙（２，３-丁二烯基）-１，４-丁二胺的醫藥組成物
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
US10585101B2 (en) 2016-03-10 2020-03-10 Wavesense, Inc. Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU199694B (en) * 1988-05-10 1990-03-28 Innofinance Altalanos Innovaci Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives
DE3918543A1 (de) * 1989-06-07 1990-12-13 Boehringer Mannheim Gmbh Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie
IL101245A0 (en) * 1991-03-20 1992-11-15 Merck & Co Inc Pharmaceutical compositions for the treatment of prostatic cancer
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer

Also Published As

Publication number Publication date
NO991192L (no) 1999-04-28
US6300313B1 (en) 2001-10-09
IL128331A0 (en) 2000-01-31
TR199900556T2 (xx) 1999-07-21
EP0925069A1 (en) 1999-06-30
HUP0000261A3 (en) 2001-03-28
WO1998010781A1 (en) 1998-03-19
NO326207B1 (no) 2008-10-20
EP0925069B1 (en) 2007-08-22
AU738306B2 (en) 2001-09-13
CA2215015A1 (en) 1998-03-12
CZ80899A3 (cs) 1999-11-17
ES2289764T3 (es) 2008-02-01
KR20010029495A (ko) 2001-04-06
SK30199A3 (en) 2000-03-13
SK286174B6 (sk) 2008-04-07
HUP0000261A2 (hu) 2000-10-28
JP2001500500A (ja) 2001-01-16
DE69738045T2 (de) 2008-05-15
KR100546235B1 (ko) 2006-01-26
PL332085A1 (en) 1999-08-30
EE9900121A (et) 1999-10-15
US6054432A (en) 2000-04-25
DE69738045D1 (de) 2007-10-04
IS4978A (is) 1999-02-16
NO991192D0 (no) 1999-03-11
ATE370743T1 (de) 2007-09-15
IL128331A (en) 2010-05-31
CN1126566C (zh) 2003-11-05
AR009757A1 (es) 2000-05-03
US5998377A (en) 1999-12-07
CN1230121A (zh) 1999-09-29
MXPA99002420A (es) 2004-08-27
NZ334540A (en) 2000-07-28
PT925069E (pt) 2007-10-17
PL193184B1 (pl) 2007-01-31
IL189132A0 (en) 2008-06-05
AU4619897A (en) 1998-04-02
RU2215537C2 (ru) 2003-11-10
US6071882A (en) 2000-06-06
TWI224002B (en) 2004-11-21
HK1021937A1 (en) 2000-07-21
DK0925069T3 (da) 2007-10-29
CZ298738B6 (cs) 2008-01-09
EE04000B1 (et) 2003-04-15

Similar Documents

Publication Publication Date Title
BR9713197A (pt) Meios para tratamento de hipertrofia de próstata e câncer de próstata
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
ATE235257T1 (de) Zusammensetzung für behandlung von maligner tumore und ihre metastase
BR0009016A (pt) Composição de apomorfina e sildenafil
EP1027011A4 (en) ADMINISTRATION OF 5-HT RECEPTOR AGONISTS AND ANTAGONISTS INCLUDING ACTIVE SUBSTANCES FOR THE TREATMENT OF EARLY SEED EATING
HUP0003194A2 (hu) Triozin-kináz-gátló alkalmazása prosztatarák kezelésére szolgáló szinergista gyógyszerkészítményben
ATE518540T1 (de) Beta-lactam verbindung enthaltende neurotherapeutische zusammensetzung
RU99107280A (ru) Фармацевтический препарат для лечения гипертрофии простаты и рака простаты и способ лечения
NZ514628A (en) Use of inhibitors for inducing cancer cell death and tumor regression
BR0009835A (pt) Formulação farmacêutica, uso da mesma, métodos para tratamento profilático ou terapêutico de um indivìduo que sofre, ou susceptìvel à hipercolesterolemia, e a diarréia, e, uso de um aglutinante de ácido da bile
WO2000038665A3 (en) Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
TR199700930T2 (xx) Ereksiyon bozuklu�unu �nlemek i�in y�ntem ve kit.
MY106484A (en) Combination therapy for phophylaxis and/or treatment of benign prostatic hyperplasia.
NZ325060A (en) Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone
HUP0004347A2 (hu) Vegyületek női szexuális diszfunkció kezelésére
PL309596A1 (en) Application of anticonvulsant agents in treating parkinson disease and parkinsonian syndromes
BG105534A (en) 5ht1 means and method for the treatment of migraine
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
SG188700A1 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
GR3024157T3 (en) Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy.
TR200200359T2 (tr) Cgrp Antagonist&#39;lerinin ve cgrp-release (Gevşeme)-Engelleyici Menopoza Bağlı Deri Kızarıklıklarında Kullanılması
TR200102107T2 (tr) Tümör nekroz faktör antagonistleri ve endometriozda kullanımları.
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
IL132853A0 (en) Combination therapy for modulating the human sexual response

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ZENTARIS AG (DE)

Free format text: TRANSFERIDO DE: ASTA MEDICA AKTIENGESELLSCHAFT

B25A Requested transfer of rights approved

Owner name: BLITZ F02-570 GMBH (DE)

Free format text: TRANSFERIDO POR FUSAO DE: ZENTARIS AG

B25D Requested change of name of applicant approved

Owner name: ZENTARIS GMBH (DE)

Free format text: ALTERADO DE: BLITZ F02-570 GMBH

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09S Decision of refusal: publication cancelled [chapter 9.2.2 patent gazette]

Free format text: ANULADA A PUBLICACAO DE INDEFERIMENTO POR TER SIDO INDEVIDA.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA (ART. 8O COMBINADO COM ART. 13 DA LPI).

B12B Appeal against refusal [chapter 12.2 patent gazette]